At Thompson we’re more than a cancer center, we’re a cancer survival center, committed to the community and determined to deliver the most advanced cancer care available. Part of this state-of-the-art treatment may include talking to you about a clinical trial.
Thompson Cancer Survival Center was the first to bring cancer clinical trials to our area in East Tennessee over 20 years ago. Clinical trials are research studies designed to answer specific questions and find better ways to treat different types of cancer. In fact, the reason why we have seen dramatic progress in recent years and treatments are continually getting better is because there are new drugs available as a direct result of clinical trials.
When your doctor discusses your diagnosis and your treatment options, he or she may talk to you about participating in a clinical trial. Whether or not you want to participate is always your decision. It’s important to ask questions and fully understand what the trial involves before making your decision.
Clinical trials bring the
most advanced treatments
to this area. |
Thompson participates in clinical trials of new cancer-fighting medicines and treatments. Current trials include new therapies for cancers including brain, breast, colon, lung, kidney, gastrointestinal, prostate, melanoma, lymphoma, leukemia, and multiple myeloma. We work with Cooperative Groups funded by the National Cancer Institute including, SWOG, NSABP, RTOG, CALGB, ECOG, NCCTG, and ACOSOG. In addition, we partner with pharmaceutical companies in order to give our patients access to new treatments that are not otherwise available.
At Thompson, we’re committed not only to providing each patient with the most advanced cancer care available, but also to leading to the cure. We offer clinical trials because it gives patients the same state-of-the-art cancer treatment they would receive if they went to any large cancer center in the country. By participating in clinical trials you are presently changing the future of cancer treatment. Be sure to learn about all of your treatment options and ask your doctor if a clinical trial might be right for you.
To learn more about currently available clinical trials at Thompson Cancer Survival Center, call the Clinical Trials Office at 541-1812 for more information.
Open trials ( Last updated 8/12/10)
| Brain |
| RTOG 0825 |
First line treatment with Conventional Chemoradiation with either Temodar + Avastin or Temodar alone for Glioblastoma |
| RTOG 0627 |
Dasatinib daily tablets for patients with Recurrent Glioblastoma who previously failed Temodar + Radiation
**Temporarily on hold for interim analysis**
|
| Breast |
NSABP
B-39/RTOG 0413 |
Conventional Whole Breast Irradiation versus Partial Breast Irradiation for early stage Breast Cancer. |
NSABP
B-43 |
Treatment with Herceptin (2 doses) for Ductal Carcinoma In Situ (DCIS) after having a Lumpectomy (HER2 testing done centrally, drug provided.) |
| CALGB 40603 |
Pre-operative treatment for Triple Negative (Estrogen and Progesterone receptor negative and HER2 -) Breast Cancer: Chemotherapy ± Avastin (Chemotherapy = Taxol ± Carboplatin with or without Avastin followed by Adriamycin + Cytoxan with or without Avastin; Avastin provided) |
NSABP
B-41 |
Pre-operative treatment for Palpable/Operable Her-2 Positive Breast Cancer: Chemotherapy plus Herceptin ± Tykerb (Adriamycin + Cytoxan followed by weekly Taxol with Herceptin, Tykerb, or both) |
| CTSU ECOG PACCT-1 |
Trial Assigning Individualized Options for Treatment of early stage Breast Cancer. Examines Tissue to Determine Risk of Recurrence and Most Appropriate and Effective Treatment (Hormonal treatment vs. Chemotherapy + Hormonal Treatment)
**Trial closes to accrual on August 20th. |
| CTSU E5103 |
Treatment For Node Positive or High Risk Node Negative, Her2 Negative Invasive Breast Cancer (Adriamycin + Cytoxan followed by weekly Taxol ± Avastin) |
NSABP
B-44 |
Treatment For Her2 positive, Node Positive or High Risk Node Negative Breast Cancer With Chemotherapy (Taxotere & Carboplatin) + Herceptin ± Avastin |
| Wyeth 3004 |
Treatment for HER2+ Breast Cancer with Neratinib/Placebo for 1 year after completion of adjuvant chemotherapy and Herceptin |
| CALGB 40502 |
First Line Treatment for Women With Locally Recurrent or Metastatic Breast Cancer with Weekly Taxol vs. Abraxane vs. Ixabepilone combined with Avastin |
| Colorectal |
| CTSU E5202 |
Tissue Evaluation With Treatment Based on Risk of Recurrence: Observation vs. FOLFOX ± Avastin in Stage II, High-risk, Colon Cancer |
| CTSU C80405 |
Trial of Chemotherapy (FOLFOX or FOLFIRI) ± Cetuximab or (FOLFOX or FOLFIRI) ± Bevacizumab (chemotherapy is physician choice) |
| NSABP R-04 |
Preoperative Radiation plus Chemotherapy (5FU ± Oxaliplatin vs. Xeloda ± Oxaliplatin) for Treatment of Patients with Operable Cancer of the Rectum
**Trial closes to accrual August 16th. |
| Gastrointestinal |
| RTOG 0436 |
First Line Treatment for Esophageal Cancer That is Not Treated With Surgery Using Weekly Chemotherapy + Radiation ± Targeted therapy (Taxol +Cisplatin + Radiation ± Cetuximab) |
| Genitourinary |
| CTSU E2805 |
Trial of Sutent, Nexavar, or Placebo For Surgically Removed Renal Cell Carcinoma (T1b (Grade3-4), T2-T4)
**Trial closes to accrual September 1st. |
| CTSU E2804 |
Treatment with Avastin, Nexavar, or Temsirolimus alone or in Combination For Advanced Renal Cell Carcinoma |
| Lung, Non-Small Cell |
| SWOG 0424 |
Tissue & Blood Molecular Epidemiology Study for Patients With Stage I - IIIB Non-Small Cell Lung Cancer |
| CTSU E1505 |
Compares Chemotherapy (Cisplatin based) ± Avastin for Patients with Completely Resected Stage 1B non-small cell lung cancer. |
| RTOG 0617 |
Compares Standard versus High-Dose Radiotherapy plus Chemotherapy (Taxol + Carboplatin) in Stage IIIA/IIIB Non-Small Lung Cancer. |
| SWOG S0819 |
First-Line Chemotherapy for Stage IV Non-Small Lung Cancer: Taxol + Carboplatin + Avastin (if appropriate, MD discretion) with or without Cetuximab followed by Maintenance therapy (if applicable-Cetuximab + Avastin (if appropriate, MD discretion) |
| Lung, Small Cell |
| CALGB 30610 |
Comparison of Radiation regimens in Patients with Limited Small Cell Lung Cancer also receiving Chemotherapy (Cisplatin + VP-16) |
| Head and Neck |
| |
None available at this time. |
| Leukemia/Lymphoma |
| CTSU E2905 |
Treatment with Revlimid ± Procrit for Low or Intermediate-1 Risk Myelodysplastic syndrome (MDS) & Symptomatic Anemia |
| SWOG C10404 |
First line treatment for symptomatic CML with Fludara + Rituxan vs. Fludara + Cytoxan + Rituxan vs. Fludara + Rituxan followed by Revlimid (consolidation) |
| Melanoma |
| ECOG E1697 |
Four weeks of High Dose Interferon -a2B vs. Observation in Early Stage Melanoma (Stage T2b N0, T3a-b N0, and T1-4, N1a-2a) |
| SWOG S0826 |
First or Second Line treatment for Metastatic Melanoma with SCH 727965 (CDK Inhibitor)
|
BMS
CA184-045 |
Compassionate Use Study of Ipilimumab For Stage III or IV Melanoma
**REOPENED! Call 865-541-1812
Must have failed or been intolerant to at least 1 systemic treatment |
| Multiple Myeloma |
| SWOG 0115 |
Treatment with Modified High Dose Melphalan/Peripheral Bone Marrow Stem Cell Transplant in patients with Multiple Myeloma (Greater than or Equal to Age 70 or Poor Renal Function) |
| CTSU BMT CTN 0702 |
Single Autologous Transplant with or without Consolidation Therapy vs. Tandem Autologous Transplant with Revlamid Maintenance for Patients with Multiple Myeloma |